MicroRNAs play important roles in the development of cancers. Although miR-92b has been reported to promote the tumorigenesis of some cancers, its role in osteosarcoma remains unknown. In the present study, we focused on the expression, function and mechanisms of miR-92b in osteosarcoma development. The miRNA miR-92b was up-regulated in osteosarcoma cell lines and tissues; miR-92b up-regulation correlated with poor prognosis in osteosarcoma. Overexpression of miR-92b promoted osteosarcoma cell proliferation, migration and invasion, which was abrogated by miR-92b inhibition. Reversion-inducing, cysteine-rich protein with kazal motifs (RECK) was identified as the direct and functional target of miR-92b in osteosarcoma. Importantly, restoring RECK expression abrogated increases in cell growth, motility and invasiveness induced by miR-92b. RECK was down-regulated in osteosarcoma tissues, and its expression level negatively correlated with miR-92b. Collectively, our results indicate that miR-92b acts as an oncogenic miRNA and may be a therapeutic target in osteosarcoma.
Skip Nav Destination
Article navigation
June 2016
-
Cover Image
Cover Image
Mitochondrial protein quality control plays a decisive role in the maintenance of a proper mitochondrial function in metabolically active tissues such as skeletal muscle. Several chaperones and proteases, involved in the regulation of mitochondrial protein quality control, are altered in obesity and type 2 diabetes mellitus. For further details see Dahlmans et al. pp. 843–852.
Research Article|
April 29 2016
Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma
Zhenhua Zhou;
Zhenhua Zhou
*Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China
†Department of Orthopaedics, 169th Hospital of PLA, Hengyang, Hunan, China
‡Department of Orthopaedics, Xiangnan Hospital, College of Medicine, Hunan Normal University, Hengyang, Hunan, China
Search for other works by this author on:
Zhiwei Wang;
Zhiwei Wang
§Department of Orthopaedics, Changhai Hospital, Second Military Medical University, Shanghai, China
Search for other works by this author on:
Haifeng Wei;
Haifeng Wei
*Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China
Search for other works by this author on:
Sujia Wu;
Sujia Wu
║Department of Orthopaedics, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu, China
Search for other works by this author on:
Xudong Wang;
Xudong Wang
*Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China
Search for other works by this author on:
Jianru Xiao
*Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China
Correspondence: Jianru Xiao ([email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
July 21 2015
Revision Received:
February 18 2016
Accepted:
March 18 2016
Accepted Manuscript online:
March 18 2016
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2016
Clin Sci (Lond) (2016) 130 (11): 921–930.
Article history
Received:
July 21 2015
Revision Received:
February 18 2016
Accepted:
March 18 2016
Accepted Manuscript online:
March 18 2016
Citation
Zhenhua Zhou, Zhiwei Wang, Haifeng Wei, Sujia Wu, Xudong Wang, Jianru Xiao; Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma. Clin Sci (Lond) 1 June 2016; 130 (11): 921–930. doi: https://doi.org/10.1042/CS20150509
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |